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3SUMMARY
There is increasing international interest in the improved timely identification and 
reporting of new and emerging drug trends. Research directed at examining drug 
trends is particularly important in the contemporary context where a variety of new 
substances are available to increasingly diverse populations and in an expanding 
range of settings. Against this background, the primary aim of this study is to take up 
the theoretical and empirical challenge of developing a methodology and a model for 
earlier identification and earlier warning of emerging drug trends. Based on the 
Bergen Earlier Warning System (BEWS), the objectives of this thesis are to examine: 
key features required for a city level drug earlier warning system; drug measures or 
‘indicators’ to the identify new and changing patterns in use; major challenges 
associated with data reliability, validity and triangulation; use of psychometrics to 
improve system validity; and how the model can report on the illicit use of medicines. 
The Bergen Earlier Warning System (BEWS) was established in 2002 drawing on 
principles derived and lessons learned from a European feasibility study conducted in 
1998 (EMCDDA, 1999; Griffiths et al., 2000). The system is multi-source (drawing 
on a range of indicators of drug use, mortality, morbidity and market characteristics), 
incorporates a mix of approaches (routine data collection, media monitoring, key 
informant study) and utilizes mixed methods (both quantitative and qualitative).
Results demonstrate that the use of the principles for psychometric scale development 
can assist with enhancing the validity of emerging drug trend monitoring systems 
(EDTMS), providing a coherent and explicit developmental framework, that has 
wider applications. A five stage review and refinement process is presented for the 
development of an EDTMS that focuses on strong construct, congruent and external 
validity. The use of a ‘pragmatic’ research paradigm is argued for in conjunction with 
a mixed method, multi indicator approach. Five criteria for indicator selection are 
4presented and it is demonstrated how these may be utilized to attribute weightings to 
individual sources in the analysis phase. Key issues relating to reliability and validity 
in the monitoring of emerging drug trends are identified, specifically challenges at the 
level of system construction, as well as reliability challenges at the level of individual 
data sources. A general approach to analysis of mixed data is proposed based on overt 
triangulation practices. A specific example of analysis is provided with reference to 
BEWS’ use of an aggregated differential score. Finally, it has been shown how the 
BEWS can be used to monitor trends in alcohol, drugs and the street use of medicines 
and report back to policy makers and practitioners for early intervention purposes.
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1. INTRODUCTION 
1.1 Background 
Drug epidemiology focuses on understanding the nature, extent, consequences and 
aetiology of drug use across individuals, families, age groups, gender, communities, 
and population groups. Epidemiologic research plays a critical public health role by 
providing an estimate of the magnitude, impact, and risk of drug use in a population, 
and by laying the foundation for developing strategies to prevent drug problems, plan 
and evaluate drug services, and suggest new areas for basic, clinical, and treatment 
research. The study of prevalence and incidence of drug use in the general population 
is, however, riddled with problems linked to small numbers of users, low reporting 
rates because of the illegal nature of drug use, and often hidden and disadvantaged 
populations who are not picked up in school or household surveys (EMCDDA, 
1999).
There is increasing international interest in the improved timely identification and 
reporting of new and emerging drug trends. Research directed at examining drug 
trends is particularly important in the contemporary context where a variety of new 
substances are available to increasingly diverse populations and in an expanding 
range of settings. Both unpredictable patterns of drug availability and evolving social 
and cultural trends influence patterns of drug consumption. The ability to detect new 
developments, for example methamphetamine use or misuse of medicines, increases 
possibilities for policy makers and practitioners to respond with informed 
interventions.
9At the international level, the Lisbon Consensus statement forms a basis for 
agreements on drug trend monitoring standards. A central issue is that of finding a 
balance between the need for comparable data and the need to develop data collection 
methods that are sensitive to local cultures and contexts. There has been international 
agreement to focus on a core data set – a limited number of indicators to be 
developed and included in monitoring systems: drug consumption among the general 
population; drug consumption among the youth population; high-risk drug abuse; 
service utilisation for drug problems; drug-related morbidity; and drug-related 
mortality. In a European context, the EU action plan on drugs calls for member states 
to provide reliable and comparable information on five key epidemiological 
indicators:
• prevalence and patterns of drug use among the general population (population 
surveys)
• prevalence and patterns of problem drug use (statistical prevalence/incidence 
estimates and surveys among drug users) 
• drug-related infectious diseases (prevalence and incidence rates of HIV, 
hepatitis B and C in injecting drug users)
• drug-related deaths and mortality of drug users (general population mortality 
special registers statistics, and mortality cohort studies among drug users) 
• demand for drug treatment (statistics from drug treatment centres on clients 
starting treatment) (Hartnoll 2003). 
This growing emphasis on emerging trend identification is reflected at the inter and 
intra jurisdiction level in many countries, for example in the recent European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) regulation under 
which the agency is called upon to play a more active role in monitoring new drug 
use patterns and emerging trends (Regulation (EC) No 1920/2006). The European 
plan on Drugs 2005 to 2008 required all European member states and Norway to 
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establish national systems for this purpose, however in reality, very few nations have 
yet been able to make much progress against this objective. The challenge is that 
traditional epidemiological research tools and core indicator data currently being used 
to monitor drug trends are insufficient to identify and rapidly report new and 
emerging patterns. 
Norway has a number of empirical studies which play a role in the monitoring of 
drug use in specific populations, primarily longitudinal surveys amongst school 
pupils (Hibell et al., 2007; Lund et al., 2007; Skretting, 2007). The Norwegian
Institute for Alcohol and Drug Research (SIRUS) produces an annual compendium of 
official drug and alcohol related statistics and special surveys entitled “Alcohol and 
Drugs in Norway” (Bryhni et al., 2009). In addition, as the Norwegian focal point to 
the EMCDDA, SIRUS produce an annual report entitled ‘The Drug Situation in 
Norway’ each year (SIRUS, 2008). Norway also reports in to the EMCDDA Early 
Warning System on new synthetic drugs (EMCDDA, 2007). However, there has been 
little research activity geared specifically towards the rapid identification of emerging 
drug trends. 
A range of drug trend monitoring systems operate internationally, most are multi-
source (drawing on a range of indicators of drug use, mortality, morbidity and market 
characteristics), incorporate a mix of approaches (for example structured 
questionnaires, semi-structured and in-depth interviews) and utilize mixed methods 
(both quantitative and qualitative). Whilst some systems adhere to an epidemiological 
surveillance methodology with an emphasis on methods precision, others take a more 
ethnographic approach, emphasizing contextual information and richness in 
description. These approaches make different assumptions about the phenomenon in 
focus, and the manner in which it is studied. There exists both methodological 
diversity in the approach to monitoring emerging trends, and lack of a coherent 
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theory base on which such systems are developed (Griffiths et al., 2000). Systems 
have developed, often ecologically, in response to differing policy needs and in 
specific political contexts. It is often unclear what the underlying hypotheses are for 
individual monitoring systems. The political, social and ideological context in which 
a system operates, for example zero tolerance or harm reduction, will impact on its 
objectives and structure. In the former, more credence might be placed on 
interdiction, policing or corrections indicators, whereas for the latter, systems might 
want to focus more on morbidity, mortality and social outcomes of drug use.
Drug monitoring systems which do make reference to a theory base tend to adhere to 
the method that is primary within the system. For example, survey-led systems 
generally refer to epidemiological paradigms (Hando et al., 1998; Kemmesis & Hess, 
2001), whilst informant focused systems cite social research and qualitative 
paradigms to explain their operation (Korf & Nabben, 2002; Mheen van de et al., 
2006a). However, an issue that is rarely addressed is the fact that most models draw 
on a mix of methodologies. Survey-led systems may also use semi-structured 
interviews with key informants and focus groups. Qualitative interview-based 
systems include school or drug user survey data. In addition, most systems include a 
range of secondary data sources. 
In general, little attention has been devoted to issues of reliability and validity in the 
context of identifying emerging drug trends. When considered, this tends to be 
explored at the level of individual information sources. However, the choice of 
sources and the way they are combined will affect and may change the results. A 
weakness common in many systems is undeveloped work on the challenges 
associated with whole system validity. There is often a poorly explained link between 
the methods described and the findings presented. Hartnoll’s jigsaw puzzle analogy 
can be used to highlight this problem (Hartnoll, 1997, p.259). Systems are able to 
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report what the individual pieces (indicators) tell about drug trends and also what the 
unfinished jigsaw puzzle appears to be showing – but there is rarely sufficient 
explanation of the strategy used to put the puzzle together. It is common practice to 
name data triangulation as a solution to reliability and validity challenges, yet the 
reasons for, and exact nature of this triangulation often remain implicit. This topic of 
drug data analysis and triangulation may be of wider interest than rapid reporting of 
emerging drug trends. Many of the same challenges exist for international, national 
and local reporting of drug use, all of which rely to a greater or lesser extent on the 
use and analysis of a range of imprecise indicator data.  
Emerging trends in the illicit use of medicines is currently high up on the 
international policy agenda. The United Nations has expressed concern that the 
variety of internationally controlled substances available on the unregulated market 
had been increasing (INCB, 2007). In addition, that drug traffickers are turning to 
innovative ways of diverting and smuggling such substances, and by making 
available medicines that are often poorly documented, unsafe, ineffective or of low 
quality, the unregulated market exposes patients to serious health risks. A recent 
summary of findings presented at the US Community Epidemiology Work Group 
found the sale of narcotic analgesic pills to be increasing as well as the diversion and 
non-medical use of prescription drugs (Maxwell, 2006). The 2006 US Monitoring the 
Future survey of 8th, 10th and 12th grade pupils indicated recent use of illicit drugs 
had dropped by 23% since 2001. By contrast, abuse of prescription opioids remained 
at ‘unacceptably high levels’ (Johnston et al., 2007).
The ongoing surveillance of the availability of medicines on the illicit drug market is 
important for a number of reasons. There are numerous adverse health consequences 
linked to misuse of medicines (Darke, 1994; Ghodse, 1995), including addiction, 
drug-related overdoses (Strang et al., 1999; Oliver et al., 2001), injection related 
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problems (Strang et al., 1994; Fry & Bruno, 2002; Degenhardt et al., 2006), and 
concerns about illicit use of prescription medicines by non-dependent drug users 
(Fountain et al., 2000; Mounteney & Leirvåg, 2005). In this context, the monitoring 
of prescribed medicines available on the illicit market allows for earlier reporting of 
emerging trends. Earlier identification increases the possibilities for earlier 
intervention and more rapid policy responses to prevent spreading and increased risk 
of drug-related harm. 
This thesis focuses on one particular function that drug monitoring systems are asked 
to perform – that of providing an early warning of the emergence of new drug trends. 
In doing so, this thesis takes up the theoretical and empirical challenge of developing 
a methodology and presents findings from a model for ‘earlier’ warning at the city 
level. Topics to be addressed are:
• Selection of drug measures or ‘indicators’ in an earlier warning system
• Challenges associated with data reliability, validity and triangulation
• The use of psychometrics to improve system validity 
• Findings with regard to the illicit use of medicines. 
1.2 Central concepts 
A number of concepts are central to this thesis and therefore working definitions are 
provided below (in alphabetical order): 
Drug indicator – can be used to describe any data source on drug use, with agreed 
rules for recording and reporting, to measure drug use prevalence or incidence. 
Typical indicators include drug seizures, treatment demand and drug overdose deaths. 
The term ‘indicator’ is used to emphasize the point that the data are not a direct 
measure of drug use in the general population (Griffiths et al. 2000). 
14
Early warning system – a drug information system designed specifically for the 
purposes of identifying changes at an early stage only. A term often used without 
precision (Griffiths et al. 2000). 
Emerging drug trend monitoring system (EDTMS) – a drug monitoring system 
with a specified objective relating to the early identification of emerging drug trends. 
EDTMS typically provide a repeat ‘situation analysis’; utilize multiple methods and 
data sources; incorporate one or more sensitive or leading edge indicator; and are 
concerned with rapid reporting of findings to the policy and practice fields 
(Mounteney et al., 2009a). 
Mixed methods – a research design with philosophical assumptions as well as 
methods of inquiry. As a method, it focuses on collecting, analyzing, and mixing both 
quantitative and qualitative data in a single study or series of studies. Its central 
premise is that the use of quantitative and qualitative approaches in combination 
provides a better understanding of research problems than either approach alone
(Creswell & Plano Clark, 2007).
Monitoring – the intermittent performance and analysis of routine measurements, 
aimed at detecting changes in the environment or health status of populations. 
Surveillance refers to a continuous process (Last, 2001). 
Multi-indicator model – used to describe a common method for modelling patterns 
of drug use that utilizes and contrasts two or more different indicators of drug 
consumption (Griffiths et al., 2000). 
Trend – movement in one direction of a variable over a period of time (time series 
data). A trend is dependent on the time range considered. An essential feature is that 
the movement, while possibly irregular in the short term (fluctuations) shows 
movement consistently in the same direction over a longer term (Griffiths et al., 
2000). An emergent drug trend can include the introduction of a new drug, a new 
combination of drugs, a new way of using an existing drug and a significant increase 
or spread in use of an existing drug into new groups or populations. Within the 
15
BEWS reporting, a trend is defined as consistent changes over two or more years – 
four (six monthly) data points (Mounteney et al., 2009b). 
Triangulation - refers to the combination of two or more theories, data sources, 
methods or investigators in one single study of a single phenomenon to converge on a 
single construct. Mutual validation involves cross checking findings from multiple 
sources against each other, on the basis that if a finding passes a series of tests with 
different methods, it can be considered more valid than with just one (Denzin, 1989, 
Patton, 1990).
1.3 Emerging Drug Trend Monitoring
This study takes as a starting point previous research undertaken on the development 
of drug information systems with an early warning objective or function. 
Internationally, there are numerous drug information systems in existence which 
employ diverse methods in order to provide an early identification and monitoring of 
drug trends (see table 1). No single blueprint exists stating what drug information 
systems (DIS) should look like or what specific tasks they should perform. An 
evolutionary process has produced a range of different models who share common 
features but whose configuration owes much to the socio-political context in which 
they were developed. Griffiths and colleagues (2000) reviewed 22 such systems, and 
differentiate between drug information systems in relation to: operational level 
(city/local, national or international); structure (organisational system or human 
network); function (early warning or multi function); range of data sources; and 
investigation method (continuous monitoring or outbreak investigation). Since then, 
there has been a continued growth in new models, ranging from international systems 
(Alvarez et al., 2003), to those focusing at a city level (Kemmesis & Hess, 2001; 
Mounteney & Leirvåg, 2004).
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At the international level, the Inter-American Drug Abuse Control Commission 
(CICAD) plays an important role in monitoring drug use in the Americas. The 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is 
responsible for collecting data and reporting on drug use in Europe. UNODC 
supports the Accord network in Asia (UNODC, 2006) and is working to establish 
regional systems elsewhere. The collaborative European Trend project was 
established to identify and understand early changes in drug use or new drugs more 
quickly than by using standard monitoring systems (Alvarez et al., 2003).  
At a national level the Illicit Drug Reporting System (IDRS) in Australia, has been 
monitoring trends since 1996 (Darke et al., 2001; Topp et al., 2004). Similarly, the 
national US Pulse Check system, utilising three key informant samples to inform on 
national and local trends, was established in 1995 (ONDCP, 2002). At the city level, 
the Antenna project has been providing annual updates on the youth and drug scene 
in Amsterdam since 1993 (Korf & Nabben, 2002). A two year research study in 
Berlin (Domes & Kraus, 2002) explored the ability of professional informants to 
accurately identify new drug trends as verified by statistical sources. And more 
recently, Frankfurt has developed the MoSyd system for monitoring drug trends, 
comprising an open scene survey, a school survey and a trend scout panel in order to 
monitor the Frankfurt drug scene (Kemmesies & Hess, 2001). New models appear 
regularly e.g. the Youth Drug Reporting System in Melbourne (Gray, 2004) and 
Vancouver (Duff et al., 2006), and the New Zealand Illicit Drug Monitoring System 
(Wilkins, Girling & Sweetsur, 2007). 
Several national drug information systems monitor illicit use of medicines alongside
other narcotic drugs, including the US Community Epidemiology Work Group 
(NIDA, 2005), Australia’s Illicit Drug Reporting System (Hando et al., 1998) and 
South Africa’s SACCENDU (Parry et al., 2002).
17
1.4 Challenges with developing a system  
By definition, the identification of new drug trends requires information to be 
collected on behaviours that have previously been unidentified. New trends in 
populations already monitored may also remain undetected as no existing routines or 
codes cover the topic. When the behaviour occurs in a new population, even greater 
difficulties exist. However it is reasonable to assume that information exists, it is just 
not collected or collated. It remains ‘trapped’ and not available to inform policy 
development. 
The 1999, the European Monitoring Centre on Drugs and Drug Addiction feasibility 
study highlighted a number of challenges that would need to be addressed by drug 
information systems aiming for the timely and reliable reporting of emerging drug 
use trends (EMCDDA, 1999). It concluded that the majority of traditional drug 
information systems, whether treatment databases, seizures figures or schools 
surveys, have not been developed with the rapid reporting of new drug phenomena in 
mind. With such systems there is generally a considerable time lag between the 
collection of data and reporting of findings. In addition, instruments such as surveys 
and databases require the addition of new codes each time a new topic is to be 
investigated. In particular, traditional drug information systems were found to 
provide relatively poor information on recreational drug use and new drug trends. 
Arguably the most intractable issue for drug monitoring systems to address is this 
need for temporal relevance. The challenge is that reliable data on the existence of a 
new pattern are only likely to become available after it has become established. In 
addition, information systems are faced with the problem that the collection and 
reporting of data is often a time consuming business. The EMCDDA feasibility study 
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included a review of the UK literature documenting the emergence of the heroin 
smoking epidemic in the late 1970's and the emergence of ecstasy use in the late 
1980's, which highlighted the existence of cultural and time gaps between emerging 
drug trends and drug information systems (Griffiths et al., 2000). In both cases many 
years elapsed between early media reports of the new trend and official reports from 
governmental or scientific sources. Such gaps represent obstacles to the rapid release 
of information to scientists, policy makers and service providers about new or 
changing patterns of drug use and their associated health risk (EMCDDA, 2001). The 
study identified a pattern of information diffusion, as details of the appearance of a 
new drug trend were recorded in the public domain. The first to write about new drug 
trends were the youth cultural press, shortly followed by the tabloid newspapers. The 
next written sources were annual reports from street agencies followed by customs 
seizures figures. This suggested a number of key information sources that could be 
considered for inclusion in a rapid reporting system. 
In general, drug monitoring systems have to rely on indirect indicators of drug 
consumption rather than direct measures. As no single data source is capable of 
providing a reliable picture of drug use, use of multi-indicators and methods is the 
rule rather than the exception. However, the establishment of multi-indicator systems 
creates numerous methodological challenges. These include: the identification and 
collection of relevant sources of drug data; the coordination and standardisation of 
diverse data sets; and the cross referencing, weighting and analysis of data sets in 
order to provide a coherent picture. In terms of data source selection there are 
challenges relating to inclusion and exclusion criteria. Decisions need to be made as 
to which aspect of drug use data sources are measuring (drug consumption, health 
consequences, availability, public concern) and which populations are covered. 
Ideally, a balance needs to be found between sensitive and routine sources. The 
selection of methodological approach raises issues, such as whether it is realistic to 
combine sources from different epistemological and phenomenological traditions? 
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However, perhaps the greatest methodological challenge relates to choice of analysis 
procedures. All drug trend monitoring systems combine sources to some extent, the 
key question is how. Researchers need to give consideration to weighting of diverse 
indicators in the analysis and choose a method for triangulation. A risk here is 
resorting to the presentation of findings from different methods and sources in 
parallel, with little integration, not uncommon in mixed methods studies (Bryman, 
2007). In reality we find a black box here for many systems, with the focus on a final 
product or report resulting in a dearth of methodological description.
A major challenge confronted ‘head on’ by this thesis is how can EDTMS 
demonstrate effectiveness – how can they show they ‘work’, in the sense that they 
succeed in the rapid identification of emergent drug phenomena. Many systems 
incorporate and utilise the very sources against which they might otherwise be 
evaluated. A local EDTMS might use national sources to compare for congruence in 
findings, however this would in many ways conflict with the knowledge that local 
patterns and variations in drug consumption do exist (Mheen van de et al., 2006b), so 
what happens nationally may not be a useful guide. Any analysis of ‘success’ would 
necessarily be retrospective, yet if an EDTMS was truly successful it would actually 
play a role in preventing the development of emerging trends by flagging and 
provoking a policy or practice response. If it is difficult to prove effectiveness by 
external comparison, an alternative approach, and one taken here, is to focus on 
system reliability and validity, in essence attempting to ensure the monitoring ‘tool’ 
is as considered and precise as possible. The in-depth focus on methodology is 
therefore an attempt to ensure any results or publicly reported findings are 
trustworthy and valid. 
There are additional challenges specific to the monitoring of new and emerging 
trends in the diversion and illicit use of medicines. As with all illegal and stigmatized 
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behaviours, monitoring is plagued by under reporting, hard to reach samples, hidden 
populations, small numbers, and a dearth of reliable prevalence data (Hartnoll et al., 
1998). Levels of incidence and prevalence of illicit use of medicines are not easily 
assessed through traditional health or social service channels (Hartnoll et al., 1998).
There are multiple sources supplying medicines to the illicit market which can make 
surveillance complex, ranging from organised international criminal networks, theft 
from pharmacies and surgeries, forgery of prescriptions, procuring from family or 
friends, to individual users diverting small amounts of prescribed drugs (Fountain et 
al., 2000). The illicit medicine market is unpredictable and characterised by ‘doctor 
shopping’, ‘multiple scripting’, and ‘overscripting’ (McKeganey, 1988; Dale & 
Jones, 1992). Finally, the thriving global market linked to the internet sale of 
medicines from e-pharmacies, is particularly difficult to monitor.
1.5 Theoretical underpinnings 
Choice of research paradigm - pragmatism 
It is proposed that the ‘pragmatic’ research paradigm offers a useful starting point for 
the consideration of systems focusing on identification of emerging drug trends. 
Pragmatism as a general belief system has been used to justify combining qualitative 
and quantitative methods in the social sciences (Johnson & Onwuegbuzie, 2006). The 
pragmatic paradigm is concerned with applications and solutions to problems (Patton, 
1990; Morgan, 2007). The research problem is most important, and researchers use a 
variety of approaches to understand the problem (Rossman & Wilson, 1985). It does 
not require commitment to any one philosophical system (Creswell, 2003) and 
researchers are free to choose methods that best meet their needs and purposes. It 
provides a philosophical underpinning for mixed method studies (Tashakkori & 
Teddlie, 1998). The pragmatic approach provides a flexible and strategic method for 
collecting and analysing data, useful as most drug trend monitoring research happens 
in environments that are both fluid and demanding of precision and timeliness. 
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Importantly, this approach also requires a clear rationale for choice of mixed/multiple 
data sources, and that attention is given to reliability, validity and triangulation issues. 
Trend theories 
The study of drugs and drug use is a truly multidisciplinary area. Depending on the 
discipline, drug use can be considered an illness (health and epidemiology), a social 
problem (social sciences), a cultural issue (anthropology and cultural studies), a 
criminal behaviour (legal studies and criminology), or drugs can be seen as a 
commodity (economics). As a result, a wealth of theoretical perspectives are available 
for the study of drug trends. Of particular importance to this study is literature that 
attempts to explain the reasons for and patterns in the way drug trends and epidemics 
develop (Kemmesies & Hess, 2001; Agar, 2001). Theories on the diffusion of 
innovation from the field of business and marketing have been used to explain 
patterns in drug use development within certain communities (Ferrence, 1994; 
Rogers, 1995; Golub & Johnson, 1996). Theories on the impact of social exclusion 
on trend development can also be found (Agar, 2001). More recent work on data 
modelling and drug trend development is also of interest (EMCDDA, 2001; Agar et 
al., 2004; Ritter, 2005) as is the potential for ‘futures’ methodologies such as scenario 
planning, to provide useful insights into the way trends can be detected (Caulkins et 
al., 2003; OST, 2005). Theory from three broad arenas: 1) public health 2) economics 
and marketing 3) social and cultural studies can be used to shed some light on two 
areas central to the development of EDTMS – trend behaviour, in particular patterns 
of diffusion, and key populations. These are briefly summarised below and possible 
implications for EDTMS development are drawn. 
Health and epidemiological theories 
The primary biomedical diffusion model follows an infectious disease route, with an 
infected (drug using) agent spreading ‘disease’ to a wider population. Such a model 
highlights the infected agent and ‘susceptibles’ as key players in trend diffusion. The 
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notion of 'epidemiological stages' assumes the spread of drug use is strongly linked to 
limits and bounds, primarily age, social status and geographic factors, which are the 
central differentiation criterion in classical epidemiology. The starting point of these 
theoretical models, named threshold model, critical-mass model or contagion model, 
refers to the idea of critical levels of incidence of a phenomenon in populations (Bless 
et al., 2002). If incidence stays below this point, the prevalence tends to gravitate 
toward some relatively low level equilibrium. But if incidence reaches the critical 
point, the process of spread can explode. Epidemiologists speak of a 'tipping or 
turning point', the point at which the usage of a drug can either turn into a serious 
public health problem, or, into a phenomenon remaining restricted to smaller user 
circles causing no striking social or health problems. Epidemiological models suggest 
the need to include drug users and their contacts (infected agents and susceptibles) 
within an EDTMS. In addition, they highlight the need to differentiate between an 
isolated or limited outbreak, and the tipping point for an emerging epidemic, where 
consumption spreads more widely to different populations. 
Economic and marketing models 
When drugs are viewed as a commodity, the classic diffusion of innovation and new 
technology models as described by Rogers (1995) lend themselves to our purpose. 
Rogers identifies a diffusion pattern with initial rapid take up of a new product 
followed by a slower spread through the wider population. The players most likely to 
try or buy a new commodity first, he calls innovators, closely followed by a group 
called early adopters. This suggests a system aiming for rapid identification of 
emerging trends needs ongoing contact with likely drug using innovators and early 
adopters. Economic theories of supply and demand are widely used in the study of 
drug markets with the common policy goals of supply reduction and demand 
reduction drawing on this model. A reminder here to include drug market indicators, 
linked to drug availability, price and purity in an EDTMS. 
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Social and cultural theories 
Cultural theorists draw on both sociological and business models to explore trends. A 
new cultural trend may well be complex and multifaceted rather than simple – thus 
leading to discussion of new configurations of existing phenomena. In drug use 
settings this might involve new ways of using existing drugs, new modes of 
administration, or new cultural linkages between drugs, music and fashion. Social 
and cultural theorists emphasize the importance of cultural readiness and receptivity 
to a new trend – that the cognitive and material conditions need to be in place for a 
new trend to take root and develop (Kemmesis, 2002). Kemmesies identifies the 
importance of a pro drug mindset, which may be measured using a semantic 
differential tool (Kemmesis, ibid). Agar stresses the role of the circulation of cultural 
narratives in social networks – ‘the buzz’ – in the development of new trends.  
Agar’s concept of ‘open marginalisation’ - the idea that certain population groups are 
marginalised from power and more susceptible to developing problem drug use – has 
been used retrospectively to explain heroin trends (Agar & Reisinger, 2001). In the 
context of the Antenna early warning system in Amsterdam, Korf & Nabben (2002) 
identify two particular youth subcultures both associated with new trends in drug use: 
1) Avant garde youth - clubbers/party goers. These tend to be middle class young 
people, keen to be at the forefront of new social trends (including drug use). They are 
not generally in touch with social services or drug treatment services and are often 
linked with synthetic drug use.  2) At risk youth - vulnerable young people. These 
young people can include school truants, those in touch with the criminal justice 
system, those in social care etc and tend to be from more deprived backgrounds. They 
can be the first to experiment with ‘harder’ drugs such as crack cocaine and injectable 
substances. Korf & Nabben also highlight two different diffusion processes for new 
drugs, concluding that ‘avant-garde’ drugs, such as new synthetics, often make a 
downwards career movement from middle class to working class users, whilst 
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‘problem drugs’ such as heroin and crack, tend to stay amongst disadvantaged and 
marginalised groups.  
These theorists remind us of the importance of taking a broad social and cultural 
perspective, using cultural mapping to help identify both marginalised and avant 
garde populations, as well as the cultural conditions and mindsets open to 
experimenting with new substances. In order to follow the ‘buzz’ and circulation of 
stories, we need to keep close contact with the user milieu, internet chat rooms and 
youth media. Taking on board the broad cultural trend definition, we are reminded to 
keep an openness to qualitative changes in consumption patterns, new and changing 
configurations, not merely new substances or quantitative increases or decreases. 
More recently theorists in all the above disciplines have explored the potential of 
complexity theory to explain trends – moving away from linear models to non linear 
dynamic models, better able, they argue to explain patterns and developments in 
complex systems such as emerging trends in drug use. Proponents such as Agar & 
Reisinger (2004) have incorporated complexity theory and agent based modelling in 
there work to attempt to develop a unified drug trend theory.  
1.6 Aims of the study 
The primary aim of this study is to take up the theoretical and empirical challenge of 
developing a methodology and a model for earlier identification and earlier warning 
of emerging drug trends. Based on the Bergen Earlier Warning System (BEWS), the 
specific aims of the thesis are to examine:
• key features required for a city level drug earlier warning system  
• drug measures or ‘indicators’ to the identify new and changing patterns in use
• major challenges associated with data reliability, validity and triangulation
• use of psychometrics to improve system validity  
• how the model can report on the illicit use of medicines. 
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2. METHODS 
2.1 The BEWS method 
The Bergen Earlier Warning System (BEWS) was established in 2002 drawing on 
principles derived and lessons learned from a European feasibility study conducted in 
1998 (EMCDDA, 1999; Griffiths et al., 2000). The system is multi-source (drawing 
on a range of indicators of drug use, mortality, morbidity and market characteristics), 
incorporates a mix of approaches (routine data collection, media monitoring, key 
informant study), and utilizes mixed methods (both quantitative and qualitative).
Preparation stage 2001-2002 
Review of empirical and theoretical literature
A comprehensive literature review provided the basis for system development. This 
has been discussed in detail earlier. 
Review and selection of data sources 
A wide range of services in the city and region were contacted asking for details of 
what drug/alcohol-related data they collected. In total over 50 different data sources 
were reviewed for possible inclusion in the project. These ranged from statutory 
organisations such as the police and customs to cultural sources such as youth 
magazines and the internet. All sources were reviewed against the following criteria: 
• Relevance – is the data relevant for the project? 
• Reliability – how reliable is the data provided? 
• Timeliness – can this data source report six monthly? 
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Figure 1. 
•Ongoing 6 monthly data 
collection and reporting
•Recruit new data sources
•Refine analysis procedures
•Refineme reporting format
•Repeat cultural mapping & 
reader feedback surveys
•First round of data collection
•Develop data analysis tools 
•Establish data collection & 
reporting framework
•Establish reporting & 
dissemination systems
•Review and refinement
•Review literature
•Review available data sources
•Recruit data providers and 
develop protocols
•Cultural mapping
•Recruit key informants
•Establish working/expert group
Preparation stage 
(2001-2002)
Piloting stage 
(2002)
Implementation & 
refinement
(2003-2009)
Stages in Føre Var system development 
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Of the sources reviewed, only seven initially matched up to the project criteria with 
the majority falling short on the timeliness issue. Drug services, for example, tended 
to report annually, with data up to two years old by the time of publication. Social 
services held individual case notes on drug users but no systematized or ongoing 
monitoring data. The main developmental stages are shown in figure1. 
Data collation protocols
Protocols were drawn up individually with each data provider, dependent on the 
format of the raw material. For example, police seizure statistics were provided 
verbally in a meeting, then collated into six monthly tables. Helpline data was sent in 
SPSS files, and alcohol data sent as pivot tables which required transferal into six 
monthly tables. 
Cultural mapping & recruitment of key informants
In addition to collecting existing data on drugs and alcohol,  a panel of key 
informants was established to provide an additional source of high quality 
information from local ‘experts’ on the city drug scene. The aim was to incorporate 
the voices and observations of young people and drug users themselves, plus the 
experiences of the wide range of professionals in close daily contact with them. 
A detailed mapping of drug and alcohol using ‘scenes’ and arenas in the city was 
undertaken prior to the establishment of the key informant panel. The objective was 
to look beyond the injecting drug scene, into current youth trends and subcultures. 
This process involved interviews with a broad range of individuals in the city with a 
focus on youth sub-cultural trends and the associated alcohol and drug using patterns. 
Four detailed maps were developed with the assistance of interviewees, focusing on 
the broad themes of: music arenas, leisure, geographical hotspots, risk groups, and 
associated drug use patterns. 
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In order to map the diverse music scene, for example, contact was made with record 
shops, music promoters, local DJs, dance instructors, club owners and young people 
themselves in order to build up an accurate map of the current youth and music 
milieu in the city. There followed questions on what types of drug use were linked to 
the different genres and clubs. This same process was used to draw all four maps. The 
final step was to create links between the maps. For example those involved in the 
rap/hip hop culture, primarily used cannabis, visited one or two particular clubs and 
had close links with the graffiti and skating culture in the city. 
A last step involved analysis of the maps and identification of differentiated scenes 
where drug use appeared to be taking place, and begin the search for a key informant 
with close links to the scene to join the panel. It was particularly important to avoid 
recruiting informants from the same scene - a worst case scenario would have been 
for a high number of the informants to report on the activities of a small group of 
drug users, thus giving a false impression of a much broader drug using trend in the 
city.
The avant garde and at risk youth theory (Korf & Nabben, 2002) was taken as an 
initial hypothesis for the BEWS project and used to underpin the cultural mapping 
and identification of key informants. Korf & Nabben provide a list of potential key 
informants, with a balance of young drug users themselves, cultural companions and 
professionals in close contact with drug users: -  DJ, club bar staff, pub doorman, 
drug dealer, student events officer, hospital accident & emergency staff, police 
officer, drug users, outreach workers, ethnographic researchers. The BEWS team 
used this as a rough guide for the final selection of key informants. However, in spite 
of numerous interviews with members of the city’s musical and artistic milieu, as 
well as the gay community, members of Bergen avant-garde scene proved elusive. In 
reality, this city with a population of approximately 250,000 has a relative integration 
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of scenes, and as one informant explained, until quite recently both those described as 
‘avant-garde experimenters’ and ‘at risk youth’ could sometimes be found in the 
same clubs and pubs. As a result we redrew the model for Bergen, developing a new 
framework focusing on three primary arenas in order to provide a starting point for 
recruitment of key informants:
1) At risk/problem drug use. Informants with knowledge about risk scenes and 
problem drug using populations (e.g. sex workers, outreach staff, treatment 
professionals)
2) Nightlife. Informants with knowledge of Bergen music, club and nightlife 
scenes (e.g. bar staff, doormen, clubbers) 
3) Community. Informants with a broader view on drug use in Bergen (e.g. 
police, emergency services, school staff, health services). 
20 informants were recruited for the piloting phase – the number was extended to 30 
for subsequent data collection rounds. 
Establishment of working group and expert group 
An important mechanism for both the cultural mapping and identification of key 
informants was the establishment of a working group with street workers from the 
outreach agency in Bergen. In addition to possessing a great deal of local ‘youth 
culture’ knowledge, the workers were also able to make introductions to potential 
informants, act as gatekeepers, and vouch for the researcher’s credibility. In addition, 
the group provided an invaluable venue for discussion of preliminary findings, 
checking out rumours and sharing of concerns. An expert group was also established, 
comprising representatives from drug treatment, criminal justice, research and policy 
sectors. This group meets twice a year and acts as an important quality assurance 
mechanism.
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Piloting Stage (2002) 
The first pilot report was used to test the feasibility of six monthly data collection 
from the selected sources – 7 routine sources, 3 media sources, and a school survey. 
An analysis system was established using SPSS for the key informant survey, 
alongside data tables with weightings – this is described in more detail in the analysis 
section. In addition, a reporting format and dissemination methodology was 
developed. There followed an in depth internal evaluation report with 
recommendations on the feasibility of full implementation. 
Implementation & refinement (2003 to 2009) 
The system was fully implemented in 2003 and has been reporting publicly at six 
monthly intervals since. Reports are published in June and December, summarizing 
data relating to the period 1st October to 31st March, and 1st April to 30th September, 
respectively. The intensive period of data collection, analysis and report writing 
therefore takes place in a two month time slot. The project cycle is presented in 
diagram form in paper 1. As of June 2009, 13 six monthly reports have been 
produced.
The project has been developmental, based on continuous evaluation, and refinement 
of tools and methods. As the method itself and analysis is unique, there has been no 
blueprint to follow. Refinement has particularly focused on the use and integration of 
multiple indicators and mixed methods. Improving reliability and validity has been 
prioritised, and is a primary topic discussed in papers 3 and 4. In addition, two reader 
feedback surveys were undertaken in December 2005 and 2007 with a view to 
ascertaining the system’s reach and impact in the city, as well as to gather 
information on enhancing reporting options. 
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2.2 Use of multiple indicators/ data sources 
BEWS is a multi-indicator model and in the BEWS report from November 2008 the 
following data sources were used: 
Figure 2. Overview of information sources used by BEWS 
The most common sources used in drug trend monitoring systems are prevalence 
surveys and routine or secondary data sets, whilst systems focusing on emerging 
trends also utilise more sensitive sources such as key informants and youth media. 
The BEWS model draws on multiple drug-related indicators and data sources, 
summarised below. A full list is presented in Appendix 1. 
S
BEWS
REPORT
RAPID ASSESSMENT 
INTERNET
KEY INFORMANT PANEL 
SCHOOL SURVEY
SCHOOL PANEL 
ROUTINE DATA
LOCAL & YOUTH 
MEDIA
33
Routine/secondary data sources 
• Seizures – police, customs, prison 
• Arrests
• Ambulance overdose call outs 
• Overdose deaths 
• Prison tests 
• Treatment demand 
• Hepatitis C, HIV, AIDS (new cases) 
• Helpline calls 
• Syringe sales/ dissemination 
• Alcohol sales
• Pharmacy sales
Media/internet sources 
• Local newspapers 
• Youth culture magazines 
• Drug user websites 
• Drug professional media 
Informant panels 
• Key informant panel 
• School panel 
Local research studies 
• School drug use survey 
• Rapid assessment studies 
• Ad hoc local drug-related studies 
2.3 Mixed methods 
A number of researchers have argued in favour of the use of mixed methods for drug 
trend monitoring (Hartnoll et al., 1997; Hando et al., 1998; Griffiths et al., 2000). If it 
is accepted that all methods have their blind spots, it has been argued that multi-
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method approaches help construct a more three-dimensional and reliable picture of 
the phenomenon and are likely to produce judgement of greater validity (Rhodes et 
al., 2000). The pragmatic research paradigm presented earlier and discussed in more 
detail in paper 3, provides an underpinning for mixed method approaches, those 
utilising both quantitative and qualitative methods within the same model. The 
quantitative elements within the BEWS model include the use and analysis of 
existing statistical data sets in the form of routine indicators listed above. In addition, 
media monitoring includes substance-related searches on internet sites. Quantitative 
data is also collected via questionnaires with informants. Finally, results from the 
school survey are incorporated on a bi-annual basis. A limited amount of qualitative 
information is collected via semi-structured questionnaires, annual interviews with 
key informants and media reviews. Qualitative findings are primarily used to explain 
unexpected or inconclusive results from the quantitative sources. Ad hoc rapid 
assessment studies also provide qualitative findings which may be incorporated. 
Secondary data collection - Every six months, data from relevant secondary sources 
is collected according to agreements made with the agencies producing the statistical 
data. The majority of data is drug specific, and this is used in the system’s 
quantitative analysis (described below). Some data is related to consequences of drug 
use, for example overdoses, arrests, Hepatitis C registrations, and these findings are 
presented as separate graphs or tables in the six monthly reports. 
Registration: Information is recorded in Excel tables.
Media monitoring – BEWS incorporates a range of media sources which are 
systematically reviewed on a six monthly basis for relevant content on both drugs and 
youth culture trends. Media monitoring involves following trends in drug use on the 
internet, in youth media magazines, in local newspapers and drug professional 
publications. Between 16-18 sources are monitored. To some extent it has proved 
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possible to standardise data collection from media sources building on the hypothesis 
that the relative frequency of references to a drug indicates its potential for diffusion 
(EMCDDA, 2001). Word searches on websites and databases provide an overview of 
frequency of mention by drug. In addition paper media are scanned, and drug-related 
articles logged by substance and topic. 
Registration: Quantitative data is recorded in Excel tables. A data recording system 
has been established for collection of qualitative information.
Key informant panel - BEWS currently has approximately thirty key informants 
working with the project, ten from the risk/problem drug use arena, ten from the 
nightlife arena and ten from the wider community. They represent a mix of 
professionals, cultural companions (e.g. DJ’s, bar staff) and drug users themselves. 
All key informants complete a semi-structured questionnaire every six months and 
between six and ten are selected to participate in an in-depth interview once a year. 
Informants are selected as ‘expert observers’ of drug use and are asked to share their 
observations of drug patterns and trends during the previous six month period. 
Informants are eighteen or over, and are not asked about their own drug use. They are 
given a music voucher as a ‘thank you’ for participating.  
The questionnaire has been developed to be as user friendly as possible, as a number 
of informants have poor literacy skills and project workers cannot always be present 
to assist with its completion. In addition to observations of drug use and new drugs, 
the key informant questionnaire includes questions on drug price, purity, street 
names, health consequences, methods of use, settings for use, forthcoming problems, 
combinations, user groups and availability. 
Registration: a questionnaire has been developed for use in Bergen drawing on 
instruments developed by Korf & Nabben (2002) and Kemmesies & Hess (2001). An 
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interview schedule is developed each year in order to explore findings in greater 
depth.
School panel (Kjentmenn) - The school panel was incorporated into the BEWS in 
2003 and comprises approximately 15 representatives from Bergen secondary 
schools. These are teachers, nurses or advisors with training in drug-related issues. 
This panel focuses on drug and alcohol-related observations in school settings and 
otherwise operates in a similar way to the key informant panel described above. All 
informants answer an anonymous (simplified) questionnaire every six months. This 
questionnaire is generally sent out and returned by email.  
Local research: schools survey & rapid assessment studies - School surveys provide 
a backbone or reference point for many monitoring models and are an accurate tool to 
assess drug use prevalence and trends over time (Korf & Nabben, 2002). BEWS also 
incorporates findings from a Bergen city schools survey of over 2000 pupils (aged 
13/14 and 15/16) which is conducted on a biannual basis by the research department 
at the Bergen Clinics Foundation (Skutle et al., 2002; Iversen et al., 2008).
The school survey is one of the few BEWS sources which reports on drug use 
prevalence, whilst most other sources used in the system are indicators of 
consumption or availability. The school survey has a large sample base and provides 
a picture of drug use in a key section of school children, which is particularly 
valuable when considering the development and spreading of trends from niche 
subcultures into wider society. In this respect the survey provides a useful and 
necessary balance to other sources in the project which report more comprehensively 
on the heavier end of the drug using spectrum.  
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As a separate initiative, the BEWS team worked with the Bergen Outreach Service to 
develop a practitioner-friendly rapid assessment tool following the principles 
established by the World Health Organisation (WHO, 1998; Mounteney & Berg, 
2008). As a result, the Outreach Service is in a position to provide high quality and 
relevant local assessment studies that can be included within the analyses. Of 
particular interest is the quick time frame for the rapid assessments - they take place 
within a six month period, from planning to fieldwork to production of a report. They 
have also been used to explore BEWS findings in more depth. A salient example 
being the identification of an increase in the number of young heroin users in 2008 
(Mounteney & Flesland, 2007) which provided a basis for a rapid assessment on 
young people linked to the opiate using milieu in Bergen (Bergen Outreach Service, 
2008).
2.4 Analysis & triangulation 
Triangulation of indicators and methods is central to BEWS and a primary means of 
ensuring valid results. It is also an area that is left unexplained by many EDTMS. 
Triangulation is primarily used by BEWS for congruence – to check whether the 
findings from different sources are in agreement. Here, quantitative sources which 
can indicate trend behaviour are utilised and an aggregated differential is calculated 
(described in detail below). Triangulation is also used for complementary purposes, 
as qualitative findings help to explore and explain quantitative data. Interesting and 
ambiguous findings from the previous report are frequently included in key informant 
interviews in the next reporting cycle. Media reports are also used to help explain, 
understand or provide commentary on results that arise. Finally, existing research e.g. 
rapid assessments and other local studies may also be used to clarify the results. 
Triangulation may be concurrent or consecutive (Morse, 1991). BEWS primarily uses 
concurrent triangulation as data is collected and analysed simultaneously every six 
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months. However a degree of ‘consecutive’ triangulation occurs to the extent that key 
findings from one period may be explored in depth during the subsequent round of 
key informant interviews. In addition, possible new substances flagged in one 
reporting cycle may be given a new code in questionnaires to key informants, or in 
the school surveys in the subsequent round of data collection. 
Data analyses
The steps undertaken for six monthly data analysis are as follows: all routine and 
media data is collected and collated in tables by substance and data source. In order to 
establish a ‘common unit of analysis’ which allows for the comparison of otherwise 
disparate data types (Hilton, 2005), results are compared with those from the previous 
six months and the percentage change calculated. Each percentage is attributed a 
change value between 1 and 5 for each source/drug type unit: 1 = strong increase and 
5 = strong decrease. The scales used for attribution of change values vary from data 
source to data source and have been developed systematically, through dialogue with 
the individual data providers and after review of past behaviour of indicators (see 
paper 4 for details). Informant questionnaires are analysed using SPSS 13.0 for 
Windows, and frequency distributions are calculated. Results related to consumption 
and availability changes are also allocated a change value based on an average 
reported increase/decrease for each drug for the period, and this is added to the 
analysis grid for routine sources (see appendix 2 for example of grids).  
Change values are summed across indicators for each independent substance and a 
weighting system is used, differentiating between the validity of indicators. The 
initial weighting system drew on selected literature (EMCDDA, 1997; Hartnoll et al., 
1998), internal evaluation of previous performance of indicators within the system, 
plus in-depth discussion with information providers on the strengths and limitations 
of their data (Mounteney & Leirvåg, 2004). During the refinement process presented 
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in paper 4, weightings were reassessed in a more systematic way, although the results 
differed minimally from the earlier weights. Specifically: x4: used for relatively 
reliable consumption measures without time lag (sales, informant consumption 
reports); x3: for relatively reliable availability measures (informant availability and 
number of seizures); x2: for less reliable availability measures and concern measures 
(seizures by weight, helpline data); x1: for heavily time-lagged measures (treatment 
demand) and rapid but unreliable measures (media). 
The analysis phase results in the calculation of an aggregated differential score for 
each substance for each six month period, producing either a plus or minus value. 
These aggregated scores are plotted in to time trend graphs as demonstrated in paper 
2.
Dividing up the aggregated differential 
The refinement process resulted in the grouping of indicators into three categories, 
depending on whether they related closest to consumption, market or interest – and 
three different aggregated differentials were calculated for each substance. 
Consumption-related indicators include: use trend data from key informants and 
school experts, urine tests from prison, treatment demand data, pharmacy, and 
alcohol sales data. Availability/market indicators include: availability data from key 
informants and school experts, number and weight of seizures from the police, prison 
and customs. Public interest or ‘concern’-related indicators include: data from 
telephone help lines, local media and user websites.  
Analysis of informant interviews 
Interviews with key informants are audio taped and later transcribed. The interviews 
with key informants and qualitative findings from the semi-structured questionnaires 
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are primarily used to provide supplementary contextual information to help 
understand results from the quantitative analysis. Each year, a new interview 
schedule is devised in order to explore previous findings in more depth or to check 
out results. Examples include: identifying the characteristics and consumption 
patterns of cocaine users; exploring the range of anabolic steroid ‘scenes’; checking 
out the availability of methamphetamine in Bergen; and exploring the increasing use 
of heroin and synthetic opiates in the city (May 2009). In addition, interviewees are 
asked to explain and provide context to answers given in their questionnaire response. 
Interviews are coded by drug type and the key informant’s milieu. A simple form of 
negative case analysis is used whereby findings are gradually generalised to all cases 
during the process, by actively seeking deviant cases. In addition a form of ‘thick 
description’ is used whereby descriptive data describing major themes in a pithy way 
are incorporated into the final report (Geetz, 1973: Mheen van de et al., 2006a). 
Analysis of drug-related consequences data 
Indictors of drug-related harm and consequences are also collected alongside the drug 
specific sources. These include data where it is not possible to specify the substance 
involved – for example injecting related data such as number of syringes given out by 
street agencies and pharmacies; drug overdose call outs and deaths; data on numbers 
of people with hepatitis C and HIV/AIDS; arrests for drug/drink driving etc. This 
data is presented every 6 months in a separate chapter of the BEWS report using 
trend graphs and tables. Where possible, links are made with the primary substance-
related findings in the form of a commentary. 
2.5 Reliability & validity
Paper 3 covers the topic of reliability and validity in EDTMS in detail whilst Paper 4 
explores the potential of using psychometrics for enhancing system validity. Below, 
the key issues are summarised.
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The reliability of drug indicators or measures is important to consider when selecting 
them for use in a system, and a balance between reliable and more timely sensitive 
sources is likely to be beneficial for the system as a whole. Small sample size and 
relatively low numbers (e.g. the number of overdoses in a month), can lead to 
potential problems in ascertaining statistically significant differences over time 
(Degenhardt & Dietze, 2005). It is possible to explore the reliability of such 
measures, particularly prevalence surveys and key informant reports, using test retest 
for reliability studies (Day et al 2004). Data can be reviewed and adjusted for 
seasonal patterns, for example increased alcohol sales during Christmas festivities, in 
order to iron out short term data behaviours that do not constitute new trends. For key 
informants, it is important to assess reliability in terms of criteria such as 
knowledgeability; credibility; impartiality; willingness to respond; and the effect of 
outside constraints, and perhaps most importantly, eliminate interviewer or 
investigator bias (Kumar, 1989). However, in a drug trend identification context, 
sources that are consistently or reliably invalid can also remain of interest. Prison 
drug testing, for example, does not give a realistic measure of drug consumption 
amongst prisoners, as different drugs remain in the bloodstream for markedly 
different lengths of time (DDL, 2006). However, if these ‘errors’ remain consistent, 
then the trend data they provide will still prove useful.
The construct validity of measures - the extent to which they are able to reflect the 
emerging drug trend construct, will have implications for whether they are selected in 
the first place and for the weighting they are given in an overall analysis. The threat 
here is inadequate preoperational explication of constructs. There is also the key 
question of a source’s timeliness as an indicator of an emerging drug trend. Here, 
techniques such as time series analysis on indicator data (Gilmour et al., 2006) have 
been utilised. Issues pertaining to internal validity are relevant to development of 
survey instruments. Factors such as key informant panel dropout or mortality can 
influence the internal validity. The convergent validity of findings from individual 
42
measures will be key for triangulation and mutual validation purposes. Convergent 
validity enhances our confidence but the possibility of error remains. It is possible 
that approaches to the measurement of our construct are problematic. Of equal 
importance, non convergence of findings from sources challenges a deeper 
exploration of results in order to identify the underlying factors that cause this 
divergence.
External validity will be strengthened with repeated measures over time or with 
confirmation by the same model in another geographical context. The extent to which 
patterns in data are interpreted as a ‘blip’ or a more general trend, is to some extent 
one of external validity. Many data sources show short-term fluctuations and 
variations from one year to the next, and this cannot be taken as a reliable sign of 
change (Hartnoll et al., 1989). Transferability refers to the generalisability of 
qualitative results from one specific context to another. Cultural mapping can be a 
useful technique prior to the identification of key informants if the aim is one of 
achieving a spread of information on different sub cultural scenes (Korf & Nabben, 
2002; Mounteney & Leirvåg, 2005). 
An important question is whether an identified emerging drug trend is ‘real’. New drug 
patterns may well be short lived, contained within one geographical region or identified by 
only one data source. The primary issue is whether the emerging trend will become a public 
health concern warranting a public heath or public safety response. It is interesting to 
consider Type 1 and Type 2 errors within this framework. Reliability and validity challenges 
for drug trend monitoring systems, lie in two broad areas: at the level of individual sources 
and at the whole system level. A type 1 error – finding something that is not there would 
involve identifying a trend that does not exist. A type 2 error - missing something that is 
there – would involve a system failing to identify a new drug trend. 
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2.6 Psychometrics and refinement
Challenges related to the reliability and validity of a measurement or monitoring tool 
are not new. The field of psychometrics has explored refinement processes to 
evaluate the properties of scales for more than a century. Although there are obvious 
differences between the measurement of a psychological construct in an individual 
and the measurement of emerging drug trends at an ecological level, the problems of 
establishing reliability and validity are similar. Paper 4 presents a methodology 
derived from psychometrics that can be used to develop and refine systems geared 
towards monitoring emerging drug trends. This addresses the issue of whole system 
validity, with a particular focus on enhancing construct, convergent and external 
validity. The process involves the following steps: 1) Theoretical conceptualisation of 
the construct to be measured; 2) Score construction and metrics; 3) Weighting of 
items; 4) Examination of the prospect of factors (subscales); 5) Checking for external 
validity. The early steps geared towards ensuring construct validity were undertaken 
prior to the establishment of BEWS, in the planning and piloting stages 2001 to 2002. 
Steps 3 and 4 represent refinements of the system and took place between 2004 and 
2008. The final step, checking for external validity is ongoing, with the increasing 
number of data collection points (repeated measures over time) enhancing external 
validity as the monitoring period increases. In addition a number of other Norwegian 
localities have been running limited versions of the BEWS model and it may be 
possible to examine results across these systems in the future.
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Mounteney, J. & Leirvåg, S-E. (2004) Drugs: education, prevention and policy,
11(6), 449–471. 
This paper documents the development of the Føre Var (BEWS) model as a citywide 
‘earlier warning’ system geared towards the identification, monitoring and reporting 
of drug and alcohol trends in the city of Bergen, Norway. The paper details the 
system’s developmental stages and methodologies, making explicit the way it 
triangulates and cross references a wide range of statistical and quantitative data 
including seizures data, treatment figures, alcohol sales and a school survey, with 
information from a number of ‘leading edge’ or sensitive data sources, including 
internet sites, youth and local media, cultural mapping and key informants.  Results 
from the first three rounds of data collection by Føre Var are presented in summary 
form and conclusions drawn on the strengths and weaknesses of the model, its 
replicability as well as the potential advantages of a city level network.
3.2 Paper II. Earlier warning: a multi-indicator approach to monitoring of 
trends in the illicit use of medicines
Mounteney, J. & Haugland, S. (2009). International Journal of Drug Policy, 20, 161-
169.
3. RESULTS 
3.1 Paper I. Providing an Earlier Warning of Emerging Drug Trends: the 
Føre Var System 
This paper explores the feasibility of monitoring trends in the illicit use of medicines 
and considers potential impact for policy makers. Data collection and analysis were 
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identification and reporting of emerging trends in medicine misuse. They have a key 
role to play in providing evidence to policy makers and practitioners. 
3.3 Paper III. Challenges of reliability and validity in the identification and 
monitoring of emerging drug trends
Mounteney, J., Fry, C., McKeganey, N. & Haugland, S. (2009a). Substance Use 
Misuse. In press. 
This paper explores three inter-related areas relevant to trend monitoring that can 
benefit from a clearer focus in terms of increasing validity and reliability: the research 
paradigm to which systems adhere; the selection of sources or drug indicators utilised 
by systems; and the process of analysis used by systems to ensure valid results. The 
reliability and validity of currently utilised drug related indicators is discussed, with a 
focus on the validity of data sources as measures of emerging drug trends. The 
relevance and utility of current descriptives such as ‘lagged’ and ‘leading edge’ 
indicators are assessed. Five dimensions, against which the validity of drug indicators 
helplines, key informants and media monitoring were triangulated and an aggregated 
differential used to plot trends. Results for the four year period showed a decline in 
the misuse of Rohypnol and an increase in the misuse of Subutex. The results show 
that multi-indicator surveillance models can play a strategic role in the rapid 
undertaken using the Bergen Earlier Warning System (BEWS), a multi-indicator drug 
monitoring system. Data was gathered at six monthly intervals from April 2002 to 
September 2006. Drug indicator data from seizures, treatment, pharmacy sales, 
may be assessed in a trend monitoring context are proposed as an alternative. Faced 
with a lack of clear conceptual frameworks underpinning and driving monitoring 
systems, it is argued that a pragmatic research paradigm can be adopted as a basis for 
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Mounteney, J. Stoove, M. & Haugland, S. (2009b) Submitted
This paper presents a standardised and sequential approach to emerging drug trend 
monitoring system (EDTMS) development and refinement, that is grounded in the 
key elements of psychometrics, and illustrates its application using an established city 
level EDTMS. A five step process is presented and exemplified, incorporating: 1) 
theoretical conceptualisation of the construct to be measured; 2) score construction; 
3) weighting of indicators; 4) exploration of the prospect of categories (subscales); 
and 5) checking for external validity. The practical application of these validity 
enhancing stages are demonstrated using the Bergen Earlier Warning System 
(BEWS). In conclusion, for non traditional systems operating in a fast changing 
environment, an iterative review and refinement process (rather than a standardised 
system or instrument) has clear benefits, and can be adopted to enhance validity in 
existing EDTMS, or be used in the development of new models.  
3.4 Paper IV. Monitoring emerging drug trends: psychometrics and 
validity in earlier warning systems.  
guiding selection of indicators and helping to make explicit the concurrent or 
supplementary triangulation and analysis procedures on which valid results are 
necessarily founded. The current trend of using triangulation as the primary means of 
ensuring the validity of systems is critically reviewed and a challenge is issued to the 
field to make the analysis process more overt.
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4. DISCUSSION
4.1 Summary of results 
By adopting a ‘pragmatic’ approach, this thesis presents the establishment of a city 
level system capable of identifying, monitoring and reporting emergent trends in drug 
and alcohol use. The capabilities of a multi-indicator, mixed method approach are 
explored, with details of the development process, data gathering methods and 
reporting capabilities. The benefits of an EDTMS operating at a city level are 
discussed with reference to the possibilities for rapid collection and turn around of 
data as well as the advantages of local ownership and the relevance of results to the 
locality.
Results from papers 3 and 4 have particular relevance for other systems engaged in 
the study of new drug trends. These papers deal with a number of fundamental and 
little explored topics such as how we can bring together and analyse such diverse data 
sets, how we might explain and justify the methods we use to do so. Paper 4 borrows 
from a long established psychometric tradition of attempting to measure abstract 
traits or behaviours, where we have no obvious or direct data sources, with a view to 
demonstrating that a considered and systematic process of empirical review, 
assessment of data and consideration of its relevance to the topic can assist in 
enhancing the validity of eventual results. 
The results presented in this thesis are both theoretical – particularly in terms of 
methodology - but also empirical and applied, in terms of developing, testing out and 
refining a ‘real life’ model, the BEWS system. Papers 1, 3 and 4 explore via a 
working model, many of the conundrums and challenges in this field of enquiry. In 
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doing so it is evident that the developmental nature of this study has both strengths 
and weaknesses. Continuous improvement results in a stronger methodology, but 
requires revision and updating of datasets as new insights and understandings are 
incorporated into the model. Paper 2 focuses on results and their application, and was 
published prior to papers 3 and 4, which are primarily concerned with enhancing and 
improving the reliability and methodology of emerging drug trend monitoring. 
Development and revision in terms of data weightings resulted in little impact on the 
overall results.
Results demonstrate that the use of the principles for psychometric scale development 
can assist with enhancing EDTMS validity, providing a coherent and explicit 
developmental framework, that has wider applications. A five stage review and 
refinement process is presented for the development of an EDTMS that focuses on 
strong construct, congruent and external validity. The use of a ‘pragmatic’ research 
paradigm is argued for in conjunction with a mixed method, multi-indicator 
approach. Five criteria for indicator selection are presented and it is demonstrated 
how these may be utilized to attribute weightings to individual sources in the analysis 
phase. Key issues relating to reliability and validity in the monitoring of emerging 
drug trends have been highlighted, specifically challenges at the level of system 
construction, as well as reliability challenges at the level of individual data sources.  
A general approach to analysis of mixed data is discussed based on overt 
triangulation practices. A specific example of analysis is provided with reference to 
BEWS’ use of an aggregated differential score. Finally, it has been shown how the 
BEWS can be used to monitor trends in alcohol, drugs and the street use of medicines 
and report back to policy makers and practitioners for early intervention purposes.
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4.2 Results in context 
This thesis demonstrates that city level EDTMS alongside traditional epidemiological 
systems can play a key role in identification and monitoring of emergent trends in 
drug consumption. EDTMS such as BEWS have an inbuilt flexibility and 
adaptability. They can report more rapidly having less levels of bureaucracy. They 
can provide local targeted information - as opposed to nationally aggregated data. 
However careful and deliberate system construction is crucial, and the key to 
developing a reliable and valid system. Many international models have neglected to 
be explicit with regard to source selection, method of analysis and system reliability 
and validity. There is a challenge to the field to be more explicit around the use of 
mixed methods. One way of demonstrating system validity is to demonstrate solid 
and rigorous system development and refinement. Use of the psychometric scale 
development process is a novel means to enhance construct validity – using a 
psychological tool or approach in a drug monitoring context. To the extent that this is 
successful – it means the system is robust, internally. Such an approach might well be 
transferable to other arenas. 
These papers build on the seminal paper by Griffiths et al. (2000) – taking forward a 
number of challenges. Whilst Griffiths et al. provided a review and critique of 
existing drug monitoring systems and their potential for improving early warning 
capabilities, this thesis tests out a number of the recommendations, in a real world 
setting, including: the construction of a multi-indicator model; incorporating both 
leading edge or sensitive sources alongside routine data; using an expert/ key 
informant panel; and utilizing theory to guide system development. In doing so, this 
thesis applies research undertaken by Korf & Nabben (2002) in Amsterdam, on the 
use of key informants and trend diffusion theory, in the development of an integrated 
‘smaller city’ model. 
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The validity paper progresses work by Degenhardt & Dietze (2005) on drug 
indicators, suggesting five criteria which might be used for indicator selection. The 
discussion and use of mixed methods can be seen to complement the work of van de 
Mheen et al. (2006a) on triangulation in qualitative systems, adding a quantitative 
dimension with the use of an aggregated differential. The use of psychometric 
methods to enhance the validity of developmental models draws on limited tradition 
of transferring this methodology across disciplines – other examples include 
ecometrics and clinimetrics.
A limited literature exists on trends in the misuse of medicines. Results presented in 
this thesis demonstrate the potential for utilization of trend monitoring methods in 
this expanding arena. Use of an aggregated differential enabled the identification of 
new and emerging consumption patterns as demonstrated for Subutex and Rohypnol. 
When combined with data from key informant interviews and media monitoring a 
more complete picture can be produced. The findings suggest that the key informant 
panel may be a particularly useful and sensitive data source in this context. The 
misuse of medicines is also identified as an area with potential for impact on early 
intervention in terms of policy and practice. 
4.3 Strengths and limitations 
Strengths of the model presented include its explicit theoretical underpinning, rapid 
reporting capabilities, local/city level nature, incorporation of reliability and validity 
checks, and relatively low operational costs.
This study presents a system which has clear theoretical and empirical foundations, 
drawing on a European feasibility study (EMCDDA, 1999) and implementing many 
of the recommendations in a working model. The developmental approach described, 
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has enabled a process of continuous improvement and refinement, drawing constantly 
on the scientific and methodological literature and ensuring the system improves with 
the latest knowledge and can remain flexible to changes in the environment it was 
established to monitor. The local and city level nature of the system has had many 
advantages including the rapid and non bureaucratic collection of data and a 
proximity to information providers, practitioner and policy makers. This has 
undoubtedly enhanced a sense of ownership of the system, witnessed by the 
contribution of data at no cost in fast time.  
It can be argued that BEWS six month reporting capability provides a genuine 
‘earlier’ warning of emerging trends when compared with systems with longer 
reporting timescales. All data sources included in the quantitative analysis submit 
data within three to four weeks of the end of each the six month reporting period. 
Such rapid turnaround is only possible because of establishment of good cooperation 
and standardization of routines with partner agencies. Goodwill is an important factor 
here, and maintained by involving partners fully, via checking of findings, invitations 
to presentations of results, regular sending of reports etc. Rapid reporting allows for 
new substances, sometimes identified via key informant reports in one period, to be 
added with a new code in the questionnaire within six months. Similarly reports of 
emerging trends, such as an increase in young heroin users, can be explored using 
interviews.
The system operates at relatively low cost, largely due to the fact that the model 
utilises existing data sources, with all routine and media data being provided for free. 
The key informant panel is the only ‘new’ data source developed specifically to 
enhance the system’s coverage, however professional informants are unpaid and non 
professionals only receive a cd voucher for their time. In terms of human resources, it 
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is estimated that the system runs with roughly one half time post a year (this time 
being divided between a project manager and project worker post).
From its inception in 2001, BEWS has increased its sophistication in terms of 
analysis, validity and reporting capabilities. Presentation of findings relating to the 
reliability and validity of indicators and EDTMS fills a gap in the literature, issues 
raised relating to triangulation provide a challenge to the field as well as proposing a 
new model for data analysis. Similarly, the adoption of the psychometric model for 
scale development as a way of enhancing validity of such developmental models, 
offers a potentially unique method for others working with system development. 
Whilst BEWS incorporates a biannual school survey, it has no access to survey data 
from general population, party goers or problem users. Survey-based EDTMS are 
able to incorporate repeat cross sectional prevalence data via quantitative user and 
key informant surveys (Hando et al.,1998), something that BEWS would 
undoubtedly benefit from, but which would be prohibitive in terms of cost and human 
resources for this city based model. Ideally BEWS would also have access to hospital 
and price/ purity data – currently not available at a local level in Norway. 
Whilst in many ways a strength, the developmental nature of this study has its 
drawbacks. Here we set out with a challenge – how to effectively monitor and 
measure emerging drug trends - and have incrementally developed a methodology to 
attempt this. The scientific and empirical literature is scarce and of limited assistance. 
Existing models have been developed in other locations and may not be transferable. 
There is a real feeling of taking a step in the dark, testing the water, then evaluating 
regularly to assess whether it was a useful direction to take. The very fact that 
monitoring of new and emerging drug trends is such a new and challenging field has 
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required a focus on methodology – in particular focus on reliability and validity.  
Much of the quality checking and refinement has occurred in tandem with public 
reporting. This is clearly the nature of developmental studies – it is not viable to wait 
until everything is in place and perfect before reporting results. In the case of BEWS, 
continuous refinement has had little impact on previously published findings. Results 
from the more finely tuned 2009 model did not diverge greatly from the basic version 
established in 2003. The addition of weightings and data updating improved the 
validity of the findings and helped provide a more sophisticated analysis but did not 
essentially affect the direction or the importance of the trend findings previously 
reported.
A further limitation of this study relates to its local nature. Whilst it can easily be 
argued that the proximity to drug using scenes as well as data providers and policy 
makers has many benefits – it remains unclear whether such a model has national or 
even international relevance or transferability. Certainly national policy makers 
cannot rely on one city’s data to describe drug trends. A network of results from 
several cities might provide one solution but this is as yet untested. 
4.4 Ethical considerations
Important ethical challenges for the field of drug epidemiology as identified by Fry & 
Hall (2002) include: free and informed consent; confidentiality, privacy and legal 
hazard; and safety issues. The BEWS system works primarily with official published 
secondary data sources (treatment demand, arrests, seizures etc) where the agencies 
themselves require strict internal routines and controls in order to collect and report 
statistical data. All partner agencies provide anonymised and aggregated six monthly 
data for the project.
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Ethical considerations are particularly relevant to work with the thirty key 
informants. All are provided with information on the project (an explanation of the 
process, their role and how information will be used) at the recruitment stage and 
invited to participate. Research tools have been developed to be as simple and 
straightforward as possible, to allow informants with poor literacy skills and those 
whose first language is not Norwegian, to participate. Importantly, the key informants 
are anonymous and are not asked to provide personal information about their own 
drug use, rather they are asked for their general observations of drug trends in the 
previous six months. No information is identifiable back to individuals or places 
(club or organisation names are not reported). In addition, people under the age of 18 
are not recruited. Informant details and identifiers are not stored on computer and are 
kept separately and securely from completed anonymous questionnaires.  
The payment of participants raises issues of consent in studies involving drug users. 
Whilst common practice in countries such as the US and Australia, critics argue that 
payment can be an inducement, and be used to buy drugs (Brody & Waldron, 2002). 
Others argue that non cash methods may reflect drug user stereotypes and a 
paternalistic approach (Grady, 2001). The BEWS non professional informants are 
provided with a cd voucher as a thank you for their time – a non cash reimbursement. 
The safety issue arises in connection with interview locations and timing; interview 
content; and response to crises that may arise, amongst other things (Fry & Hall, 
2002). In the case of BEWS, face to face interviews are carried out either in public 
spaces, such as cafes or in the research offices. Interviewers are professionally trained 
to be able to handle any difficult situations that might arise.  
The epidemiological gaze may increase recognition and reporting of a problem, and 
may spuriously influence social facts such as new drug trends. The project team has 
an ethical responsibility not to become a ‘trend creator’ – something which might 
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happen if the media takes hold of a story and publishes in an irresponsible way. In 
order to prevent this happening, much energy has been put into building responsible 
relationships with local journalists and developing the local news media’s 
understanding of the project aims and objectives. A final important ethical 
consideration is how the reported results might be utilised. The intention is that 
results from the project feed into the wider public health, prevention and harm 
reduction policy making agenda and are not utilised for criminal justice or 
prosecutory purposes. Confidentiality of informants and the anonymity of data 
sources become extra important in this context.
This project has been approved by both the Regional Committee for Medical and 
Health Research (REK) and the Norwegian Data Inspectorate (Datatilsyn).
4.5 Impact and relevance for policy and practice 
Policy makers require timely and reliable information on new trends in order to make 
evidence-based decisions and plans that can minimise the public health risk and other 
potential harms of drug use. Without up to date information, there is an increased risk 
that drug policy and interventions will be based on outdated research or sensationalist 
media reports, for the simple reason that this is the only information available. 
The May 2009 EMCDDA conference focusing on Europe’s future drug information 
needs was summarised on their website with the following headline: “Experts and 
policymakers underline need for rapid and innovative responses to Europe’s changing 
drugs problem” (EMCDDA 2009a). In summarising key points from the conference, 
the Head of Epidemiology, Griffiths concluded: ‘Multi-methods approaches, 
sensitivity and timeliness are common issues for drug monitoring systems, and 
combining different types of information (qualitative/ quantitative) and levels of 
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analysis (local/national/international.), remains a key challenge’ (EMCDDA 2009b). 
In this context, the BEWS model, methods and conclusions of this thesis have much 
to offer the wider field of drug trend monitoring, both at a scientific and a policy 
level.
A primary aim for BEWS has been the early identification and reporting of emerging 
drug trends in order to facilitate timely and effective drug policy responses. One 
measure of the system’s success is whether the results reach policy makers and 
practitioners in Bergen and further a field, as well as the extent to which they elicit a 
response. In this context the dissemination of results in a policy friendly format has 
been an important consideration. In practice two ‘findings’ reports have been widely 
disseminated each year to approximately 1000 policy makers and practitioners both 
locally and nationally. An annual conference is held each December where the 
findings are presented to a broad public. In addition, results are regularly presented at 
local, national and international seminars and conferences. Several workshops 
focusing on implications of BEWS results are held each year with a mix of agencies 
including, police, prisons, ambulance services, lawyers, outreach staff, childcare 
services, treatment specialists, school heads etc. Six monthly results receive wide 
media coverage, with both national and regional television, as well as radio and 
newspapers reporting on trends. In addition, a BEWS trend column appeared in the 
national drugs journal (Rus & samfunn) between 2005 and 2006, reporting results to 
policy makers and practitioners in the field. 
Two small reader satisfaction surveys from 2005 and 2007 provide an insight into 
who the reports are reaching and how the results are being used (Mounteney, 2005; 
Flesland & Mounteney, 2007). Both samples (n=56) and (n=109) respectively were 
primarily drawn from annual conference attendees. These demonstrated that BEWS 
findings were reaching a broad range of local professionals in Bergen, ranging from 
pharmacy workers, customs officials to educational, health and social workers. On 
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average, respondents reported three different uses for the BEWS findings, most 
commonly to keep themselves informed of the latest drug trend development, but also 
using the findings as an evidence base for planning, and project funding proposals. 
Drug monitoring systems have been described as management information systems 
based on scientific methods (Mheen van de et al., 2006a). In this respect, a measure 
of BEWS’s success can be linked to the fact that results have been integrated in city 
planning mechanisms – the reports have been utilised as a source for the city drugs 
plan, in the city childcare plan as well as in the police annual report. In addition the 
results have been used in the Norwegian national drug report reports to the 
EMCDDA and as evidence in advisory meetings for the Norwegian Health 
Directorate. Data produced by BEWS has also been incorporated in the EMCDDA E-
POD studies (EMCDDA, 2008). 
The system has successfully dovetailed with other city level research studies. New 
codes have been added to the biannual Bergen schools survey – both anabolic 
steroids and Rohypnol were included after these substances were identified as being 
on the increase in younger populations. Findings on emerging trends have been cited 
as the starting point for in-depth studies and for early intervention activity. For 
example, reports of an increase in use of anabolic steroids, sparked off a project by 
the city outreach service working with young men and steroid use in Bergen. 
Similarly when BEWS flagged an increase in young heroin users, the finding was 
used as a motivator for a rapid assessment into the needs of this group (Bergen 
Outreach Service, 2008).
As described in detail in paper 2, BEWS results have much potential for adding to the 
evidence base on trends in the street use of prescribed medicines which is a topic of 
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increasing international concern at the policy level (INCB, 2007). Consistent reports 
of increases in leakage of Subutex were cited as one reason for the introduction of 
Suboxone in Bergen 2007. BEWS findings were one of many sources reporting 
increases in street use of Rohypnol and Temgesic, both of which subsequently had 
tighter prescribing restrictions imposed. Finally, EDTMS such as BEWS have a 
potential role in the evaluation of policy decisions, through monitoring the street level 
side effects of particular interventions.
4.6 Future areas for research 
This thesis takes a small step forward into a large and increasingly important arena. 
In many respects, it opens up questions and dilemmas and by no means provides all 
the answers. It challenges the field by highlighting a need to improve methods for 
monitoring emerging trends, and to consider flexible and innovative ways of doing 
this. The problem exposed, however, by use of non traditional methods, is that of 
ensuring reliable and valid findings. A number of ways forward are presented but 
there is need for more focused work in this area. Evaluation of such a system and its 
findings is difficult – necessarily retrospective – and in the case of BEWS which 
utilises almost all relevant local data sources, virtually impossible to find unused 
external sources to benchmark or crosscheck results against. Demonstrating the 
external validity of the BEWS results remains a challenge. Ideally the system needs 
results from other models for comparison purposes. A manual has been developed 
and a number of other localities have established similar methodologies with varying 
degrees of success. Following up on these will be an important area for the future. 
There are a number of additional areas that would benefit from further attention. The 
issue of factor analysis as taken up in paper 4 remains unresolved. The BEWS system 
as yet has too few time/data points to allow a useful factor solution. Follow up of this 
option in a couple of years time might well strengthen the approach. In addition the 
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qualitative dimension of the study could be developed. At present, qualitative 
methods incorporated into BEWS include interviews with key informants, the open 
questions on the key informants’ semi structured questionnaire, and review of media 
– in particular newspapers, professional journals and drug user websites. In order to 
fully benefit from the mixed methods paradigm presented in paper 3, qualitative 
methodologies could be enhanced. Work by van de Mheen et al. (2006a) provides a 
clear direction into ways this has been achieved elsewhere. 
In the field of EDTMS there are a number of areas which would benefit from further 
research and development. These include further work on the reliability and validity 
of information sources used for timely and sensitive monitoring, in particular use of 
key informants. It would be interesting to undertake test retest of interviews for 
informant reliability. Findings presented in paper 3 suggested key informants may be 
six months earlier than other sources in identification of new patterns of medicine 
misuse. This phenomenon could be explored in more depth. In addition other models 
of triangulation could be explored and developed, adding to the debate in the 
developing mixed methods arena. The theoretical underpinnings for EDTMS remain 
weak and often unstated – this is certainly an area that would benefit from further 
development both in terms of trend development and diffusion theories and their 
relevance and application for EDTMS. A particularly interesting area would be to 
link together a network of city level systems, able to provide a big picture overview 
using comparable methodologies, of national and international development in the 
drug trend arena. Finally the potential of EDTMS for policy monitoring and 
evaluation is likely to be an increasingly important field in the future. Making 
stronger links and connections between monitoring and policy makers’ needs, and 
providing useful results that answer pressing policy questions are important next 
steps.
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4.7 Concluding remarks 
To conclude, the identification of emerging drug trends is a young and inexact 
science so continuous improvement is necessary. EDTMS models will need to be in 
advance of the mainstream and flexible enough to pick up on new practices. Cultural 
monitoring will be important in order to follow youth fashions and trends. 
Monitoring systems will undoubtedly benefit from a mix of indicators – some 
traditional and some novel, able to tell us about both known and less known drug 
using populations. There is a need for flexible research tools which are quick to adapt 
in the face of new evidence. Indicators will need to be selected with due 
consideration to their reliability and validity within an overall system. Whole system 
validity can be strengthened by a process of systematic development and continuous 
refinement. Attention to the analysis and triangulation of mixed methods and multiple 
data will increase the credibility of the results. Drug use trends are fast changing, and 
the misuse of prescription medicines is one area of political concern. City level 
systems such as BEWS have the potential to make a real contribution and provide an 
important earlier warning of new developments in this area.
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